{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:08:35Z","timestamp":1762160915491},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T00:00:00Z","timestamp":1308441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T00:00:00Z","timestamp":1308441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00262-011-1065-8","type":"journal-article","created":{"date-parts":[[2011,6,18]],"date-time":"2011-06-18T08:54:34Z","timestamp":1308387274000},"page":"1181-1193","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?"],"prefix":"10.1007","volume":"60","author":[{"given":"Naomi L.","family":"Dunning","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie A.","family":"Laversin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda K.","family":"Miles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert C.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,6,19]]},"reference":[{"issue":"4","key":"1065_CR1","first-page":"493","volume":"65","author":"T Drewa","year":"2008","unstructured":"Drewa T, Styczynski J, Szczepanek J (2008) Is the cancer stem cell population \u201ca player\u201d in multi-drug resistance? Acta Pol Pharm 65(4):493\u2013500","journal-title":"Acta Pol Pharm"},{"issue":"9360","key":"1065_CR2","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(03)12713-4","volume":"361","author":"H Gronberg","year":"2003","unstructured":"Gronberg H (2003) Prostate cancer epidemiology. Lancet 361(9360):859\u2013864","journal-title":"Lancet"},{"issue":"2","key":"1065_CR3","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ctrv.2009.06.001","volume":"36","author":"F Stavridi","year":"2010","unstructured":"Stavridi F, Karapanagiotou EM, Syrigos KN (2010) Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 36(2):122\u2013130","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"1065_CR4","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.urolonc.2007.05.010","volume":"25","author":"BA Hadaschik","year":"2007","unstructured":"Hadaschik BA, Gleave ME (2007) Therapeutic options for hormone-refractory prostate cancer in 2007. Urol Oncol 25(5):413\u2013419","journal-title":"Urol Oncol"},{"issue":"6","key":"1065_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0167-5699(97)80020-5","volume":"18","author":"T Boon","year":"1997","unstructured":"Boon T, Coulie PG, Van den Eynde B (1997) Tumor antigens recognized by T cells. Immunol Today 18(6):267\u2013268","journal-title":"Immunol Today"},{"issue":"2","key":"1065_CR6","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3322\/canjclin.49.2.70","volume":"49","author":"SA Rosenberg","year":"1999","unstructured":"Rosenberg SA (1999) A new era of cancer immunotherapy: converting theory to performance. CA Cancer J Clin 49(2):70\u201373","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1065_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.critrevonc.2008.02.010","volume":"67","author":"S Pejawar-Gaddy","year":"2008","unstructured":"Pejawar-Gaddy S, Finn OJ (2008) Cancer vaccines: accomplishments and challenges. Crit Rev Oncol Hematol 67(2):93\u2013102","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"1065_CR8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S0952-7915(02)00318-7","volume":"14","author":"E Jager","year":"2002","unstructured":"Jager E, Jager D, Knuth A (2002) Clinical cancer vaccine trials. Curr Opin Immunol 14(2):178\u2013182","journal-title":"Curr Opin Immunol"},{"issue":"4","key":"1065_CR9","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nrc1586","volume":"5","author":"W Zou","year":"2005","unstructured":"Zou W (2005) Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 5(4):263\u2013274","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"1065_CR10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W (2006) Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6(4):295\u2013307","journal-title":"Nat Rev Immunol"},{"issue":"45","key":"1065_CR11","doi-asserted-by":"crossref","first-page":"5263","DOI":"10.1016\/j.vaccine.2005.06.024","volume":"23","author":"RD Weeratna","year":"2005","unstructured":"Weeratna RD, Makinen SR, McCluskie MJ, Davis HL (2005) TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848). Vaccine 23(45):5263\u20135270","journal-title":"Vaccine"},{"issue":"4","key":"1065_CR12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1399-0039.2009.01336.x","volume":"74","author":"LJ Berry","year":"2009","unstructured":"Berry LJ, Moeller M, Darcy PK (2009) Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells. Tissue Antigens 74(4):277\u2013289","journal-title":"Tissue Antigens"},{"issue":"1","key":"1065_CR13","first-page":"55","volume":"12","author":"Z Eshhar","year":"2010","unstructured":"Eshhar Z (2010) Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinic. Curr Opin Mol Ther 12(1):55\u201363","journal-title":"Curr Opin Mol Ther"},{"issue":"4","key":"1065_CR14","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-008-0598-y","volume":"58","author":"T Zhang","year":"2009","unstructured":"Zhang T, Herlyn D (2009) Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer. Cancer Immunol Immunother 58(4):475\u2013492","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"1065_CR15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8(1):59\u201373","journal-title":"Nat Rev Immunol"},{"key":"1065_CR16","doi-asserted-by":"crossref","unstructured":"Jahnisch H, Fussel S, Kiessling A, Wehner R, Zastrow S, Bachmann M, Rieber EP, Wirth MP, Schmitz M (2010) Dendritic cell-based immunotherapy for prostate cancer. Clin Dev Immunol:517493","DOI":"10.1155\/2010\/517493"},{"issue":"4","key":"1065_CR17","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1172\/JCI40269","volume":"120","author":"R Ramakrishnan","year":"2010","unstructured":"Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, Altiok S, Celis E, Gabrilovich DI (2010) Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 120(4):1111\u20131124","journal-title":"J Clin Invest"},{"issue":"5","key":"1065_CR18","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1073\/pnas.96.5.2233","volume":"96","author":"AF Ochsenbein","year":"1999","unstructured":"Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96(5):2233\u20132238","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1065_CR19","first-page":"769","volume":"18","author":"RT Prehn","year":"1957","unstructured":"Prehn RT, Main JM (1957) Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst 18(6):769\u2013778","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"1065_CR20","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1084\/jem.186.5.645","volume":"186","author":"DE Speiser","year":"1997","unstructured":"Speiser DE, Miranda R, Zakarian A, Bachmann MF, McKall-Faienza K, Odermatt B, Hanahan D, Zinkernagel RM, Ohashi PS (1997) Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med 186(5):645\u2013653","journal-title":"J Exp Med"},{"key":"1065_CR21","doi-asserted-by":"publisher","unstructured":"Nabhan C, Parsons B, Touloukian EZ, Stadler WM (2011) Novel approaches and future directions in castration-resistant prostate cancer. Ann Oncol doi:10.1093\/annonc\/mdq639","DOI":"10.1093\/annonc\/mdq639"},{"key":"1065_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0065-230X(08)60523-0","volume":"14","author":"GI Abelev","year":"1971","unstructured":"Abelev GI (1971) Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res 14:295\u2013358","journal-title":"Adv Cancer Res"},{"issue":"2","key":"1065_CR23","first-page":"219","volume":"45","author":"P Gold","year":"1970","unstructured":"Gold P, Krupey J, Ansari H (1970) Position of the carcinoembryonic antigen of the human digestive system in ultrastructure of tumor cell surface. J Natl Cancer Inst 45(2):219\u2013225","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"1065_CR24","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1084\/jem.178.2.489","volume":"178","author":"V Brichard","year":"1993","unstructured":"Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, Lethe B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178(2):489\u2013495","journal-title":"J Exp Med"},{"issue":"1","key":"1065_CR25","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/bbrc.2000.4087","volume":"280","author":"D Chen","year":"2001","unstructured":"Chen D, Shou C (2001) Molecular cloning of a tumor-associated antigen recognized by monoclonal antibody 3H11. Biochem Biophys Res Commun 280(1):99\u2013103","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1065_CR26","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0165-4608(02)00607-6","volume":"139","author":"A Line","year":"2002","unstructured":"Line A, Slucka Z, Stengrevics A, Li G, Rees RC (2002) Altered splicing pattern of TACC1 mRNA in gastric cancer. Cancer Genet Cytogenet 139(1):78\u201383","journal-title":"Cancer Genet Cytogenet"},{"issue":"10","key":"1065_CR27","doi-asserted-by":"crossref","first-page":"6416","DOI":"10.1074\/jbc.272.10.6416","volume":"272","author":"O Tureci","year":"1997","unstructured":"Tureci O, Schmitt H, Fadle N, Pfreundschuh M, Sahin U (1997) Molecular definition of a novel human galectin which is immunogenic in patients with Hodgkin\u2019s disease. J Biol Chem 272(10):6416\u20136422","journal-title":"J Biol Chem"},{"issue":"2","key":"1065_CR28","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1084\/jem.183.2.527","volume":"183","author":"JC Skipper","year":"1996","unstructured":"Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL Jr, Boon T, Hunt DF, Engelhard VH (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183(2):527\u2013534","journal-title":"J Exp Med"},{"issue":"11","key":"1065_CR29","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1136\/jcp.2007.046557","volume":"60","author":"F Demichelis","year":"2007","unstructured":"Demichelis F, Rubin MA (2007) TMPRSS2-ETS fusion prostate cancer: biological and clinical implications. J Clin Pathol 60(11):1185\u20131186","journal-title":"J Clin Pathol"},{"issue":"5038","key":"1065_CR30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","volume":"254","author":"P van der Bruggen","year":"1991","unstructured":"van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643\u20131647","journal-title":"Science"},{"issue":"3","key":"1065_CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/pros.20040","volume":"60","author":"PA Burch","year":"2004","unstructured":"Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S (2004) Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 60(3):197\u2013204","journal-title":"Prostate"},{"issue":"12","key":"1065_CR32","doi-asserted-by":"crossref","first-page":"7150","DOI":"10.4049\/jimmunol.167.12.7150","volume":"167","author":"L Fong","year":"2001","unstructured":"Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167(12):7150\u20137156","journal-title":"J Immunol"},{"issue":"4","key":"1065_CR33","first-page":"829","volume":"60","author":"PA Lodge","year":"2000","unstructured":"Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML (2000) Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 60(4):829\u2013833","journal-title":"Cancer Res"},{"issue":"2","key":"1065_CR34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3322\/canjclin.49.2.117","volume":"49","author":"BA Tjoa","year":"1999","unstructured":"Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP (1999) Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J Clin 49(2):117\u2013128","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1065_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/(SICI)1097-0045(19990701)40:2<125::AID-PROS8>3.0.CO;2-Y","volume":"40","author":"BA Tjoa","year":"1999","unstructured":"Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP (1999) Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate 40(2):125\u2013129","journal-title":"Prostate"},{"issue":"3","key":"1065_CR36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI0214364","volume":"109","author":"A Heiser","year":"2002","unstructured":"Heiser A, Coleman D, Dannull J, Yancey D, Maurice MA, Lallas CD, Dahm P, Niedzwiecki D, Gilboa E, Vieweg J (2002) Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 109(3):409\u2013417","journal-title":"J Clin Invest"},{"issue":"6 Pt 2","key":"1065_CR37","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1097\/01.ju.0000144211.51111.e4","volume":"172","author":"H Ragde","year":"2004","unstructured":"Ragde H, Cavanagh WA, Tjoa BA (2004) Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer. J Urol 172(6 Pt 2):2532\u20132538","journal-title":"J Urol"},{"issue":"12","key":"1065_CR38","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1007\/s00262-006-0157-3","volume":"55","author":"Y Waeckerle-Men","year":"2006","unstructured":"Waeckerle-Men Y, Uetz-von Allmen E, Fopp M, von Moos R, Bohme C, Schmid HP, Ackermann D, Cerny T, Ludewig B, Groettrup M, Gillessen S (2006) Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 55(12):1524\u20131533","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"1065_CR39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/08830185.2010.490777","volume":"29","author":"A Bot","year":"2010","unstructured":"Bot A (2010) The landmark approval of Provenge, what it means to immunology and \u201cin this issue\u201d: the complex relation between vaccines and autoimmunity. Int Rev Immunol 29(3):235\u2013238","journal-title":"Int Rev Immunol"},{"issue":"7","key":"1065_CR40","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.vaccine.2010.12.016","volume":"29","author":"M Krupa","year":"2011","unstructured":"Krupa M, Canamero M, Gomez CE, Najera JL, Gil J, Esteban M (2011) Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression. Vaccine 29(7):1504\u20131513","journal-title":"Vaccine"},{"issue":"12","key":"1065_CR41","doi-asserted-by":"crossref","first-page":"5798","DOI":"10.1158\/0008-5472.CAN-06-3849","volume":"67","author":"PM Challita-Eid","year":"2007","unstructured":"Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, Raitano AB, Jia XC, Gudas JM, Kanner SB, Jakobovits A (2007) Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 67(12):5798\u20135805","journal-title":"Cancer Res"},{"issue":"9","key":"1065_CR42","first-page":"2072","volume":"63","author":"N Shukeir","year":"2003","unstructured":"Shukeir N, Arakelian A, Kadhim S, Garde S, Rabbani SA (2003) Prostate secretory protein PSP-94 decreases tumor growth and hypercalcemia of malignancy in a syngenic in vivo model of prostate cancer. Cancer Res 63(9):2072\u20132078","journal-title":"Cancer Res"},{"issue":"10","key":"1065_CR43","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/00001813-200511000-00002","volume":"16","author":"N Shukeir","year":"2005","unstructured":"Shukeir N, Garde S, Wu JJ, Panchal C, Rabbani SA (2005) Prostate secretory protein of 94 amino acids (PSP-94) and its peptide (PCK3145) as potential therapeutic modalities for prostate cancer. Anticancer Drugs 16(10):1045\u20131051","journal-title":"Anticancer Drugs"},{"issue":"13","key":"1065_CR44","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.287.13.1662","volume":"287","author":"MA Rubin","year":"2002","unstructured":"Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM (2002) alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. Jama 287(13):1662\u20131670","journal-title":"Jama"},{"issue":"8","key":"1065_CR45","first-page":"2220","volume":"62","author":"J Luo","year":"2002","unstructured":"Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62(8):2220\u20132226","journal-title":"Cancer Res"},{"issue":"2","key":"1065_CR46","first-page":"130","volume":"13","author":"ZH Tao","year":"2007","unstructured":"Tao ZH, Mao XL, Wang CH, Chen XD, Yu KY, Weng ZL, Hu YP, Zhang XH, Xie H, Wang OC, Song QT, Li CD, Chen ZG (2007) Quantitative detection of DD3 mRNA in prostate cancer tissues by real-time fluorescent quantitative reverse transcription polymerase chain reaction. Zhonghua Nan Ke Xue 13(2):130\u2013133","journal-title":"Zhonghua Nan Ke Xue"},{"issue":"7","key":"1065_CR47","first-page":"2673","volume":"9","author":"ML Gonzalgo","year":"2003","unstructured":"Gonzalgo ML, Pavlovich CP, Lee SM, Nelson WG (2003) Prostate cancer detection by GSTP1 methylation analysis of postbiopsy urine specimens. Clin Cancer Res 9(7):2673\u20132677","journal-title":"Clin Cancer Res"},{"issue":"35","key":"1065_CR48","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1038\/sj.onc.1207800","volume":"23","author":"CS Foster","year":"2004","unstructured":"Foster CS, Falconer A, Dodson AR, Norman AR, Dennis N, Fletcher A, Southgate C, Dowe A, Dearnaley D, Jhavar S, Eeles R, Feber A, Cooper CS (2004) Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23(35):5871\u20135879","journal-title":"Oncogene"},{"issue":"9","key":"1065_CR49","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1093\/jnci\/95.9.661","volume":"95","author":"DR Rhodes","year":"2003","unstructured":"Rhodes DR, Sanda MG, Otte AP, Chinnaiyan AM, Rubin MA (2003) Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J Natl Cancer Inst 95(9):661\u2013668","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"1065_CR50","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-5347(05)68044-5","volume":"163","author":"C Becker","year":"2000","unstructured":"Becker C, Piironen T, Pettersson K, Bjork T, Wojno KJ, Oesterling JE, Lilja H (2000) Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163(1):311\u2013316","journal-title":"J Urol"},{"issue":"4","key":"1065_CR51","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.urology.2007.01.097","volume":"69","author":"ES Leman","year":"2007","unstructured":"Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH (2007) EPCA-2: a highly specific serum marker for prostate cancer. Urology 69(4):714\u2013720","journal-title":"Urology"},{"issue":"3","key":"1065_CR52","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/pros.20520","volume":"67","author":"AK Miles","year":"2007","unstructured":"Miles AK, Rogers A, Li G, Seth R, Powe D, McArdle SE, McCulloch TA, Bishop MC, Rees RC (2007) Identification of a novel prostate cancer-associated tumor antigen. Prostate 67(3):274\u2013287","journal-title":"Prostate"},{"issue":"3","key":"1065_CR53","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12015-008-9033-1","volume":"4","author":"S Kasper","year":"2008","unstructured":"Kasper S (2008) Exploring the origins of the normal prostate and prostate cancer stem cell. Stem Cell Rev 4(3):193\u2013201","journal-title":"Stem Cell Rev"},{"key":"1065_CR54","first-page":"155","volume":"5","author":"NJ Maitland","year":"2006","unstructured":"Maitland NJ, Bryce SD, Stower MJ, Collins AT (2006) Prostate cancer stem cells: a target for new therapies. Ernst Schering Found Symp Proc 5:155\u2013179","journal-title":"Ernst Schering Found Symp Proc"},{"issue":"7","key":"1065_CR55","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1158\/0008-5472.CAN-06-4429","volume":"67","author":"J Miki","year":"2007","unstructured":"Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS (2007) Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 67(7):3153\u20133161","journal-title":"Cancer Res"},{"issue":"1","key":"1065_CR56","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.pcan.4501018","volume":"11","author":"J Miki","year":"2008","unstructured":"Miki J, Rhim JS (2008) Prostate cell cultures as in vitro models for the study of normal stem cells and cancer stem cells. Prostate Cancer Prostatic Dis 11(1):32\u201339","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"1065_CR57","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1172\/JCI32810","volume":"117","author":"DA Lawson","year":"2007","unstructured":"Lawson DA, Witte ON (2007) Stem cells in prostate cancer initiation and progression. J Clin Invest 117(8):2044\u20132050","journal-title":"J Clin Invest"},{"issue":"23","key":"1065_CR58","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1158\/0008-5472.CAN-05-2018","volume":"65","author":"AT Collins","year":"2005","unstructured":"Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65(23):10946\u201310951","journal-title":"Cancer Res"},{"issue":"3","key":"1065_CR59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.semcancer.2006.04.004","volume":"17","author":"S Signoretti","year":"2007","unstructured":"Signoretti S, Loda M (2007) Prostate stem cells: from development to cancer. Semin Cancer Biol 17(3):219\u2013224","journal-title":"Semin Cancer Biol"},{"issue":"17","key":"1065_CR60","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1200\/JCO.2007.15.1472","volume":"26","author":"NJ Maitland","year":"2008","unstructured":"Maitland NJ, Collins AT (2008) Prostate cancer stem cells: a new target for therapy. J Clin Oncol 26(17):2862\u20132870","journal-title":"J Clin Oncol"},{"issue":"17","key":"1065_CR61","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1200\/JCO.2007.15.2702","volume":"26","author":"CD Peacock","year":"2008","unstructured":"Peacock CD, Watkins DN (2008) Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 26(17):2883\u20132889","journal-title":"J Clin Oncol"},{"issue":"3","key":"1065_CR62","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.cdd.4402283","volume":"15","author":"A Eramo","year":"2008","unstructured":"Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3):504\u2013514","journal-title":"Cell Death Differ"},{"issue":"3","key":"1065_CR63","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","volume":"67","author":"C Li","year":"2007","unstructured":"Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM (2007) Identification of pancreatic cancer stem cells. Cancer Res 67(3):1030\u20131037","journal-title":"Cancer Res"},{"issue":"7123","key":"1065_CR64","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","volume":"445","author":"CA O\u2019Brien","year":"2007","unstructured":"O\u2019Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106\u2013110","journal-title":"Nature"},{"issue":"7123","key":"1065_CR65","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature05384","volume":"445","author":"L Ricci-Vitiani","year":"2007","unstructured":"Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111\u2013115","journal-title":"Nature"},{"issue":"7176","key":"1065_CR66","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nature06489","volume":"451","author":"T Schatton","year":"2008","unstructured":"Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH (2008) Identification of cells initiating human melanomas. Nature 451(7176):345\u2013349","journal-title":"Nature"},{"issue":"17","key":"1065_CR67","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.2007.15.5945","volume":"26","author":"S Sell","year":"2008","unstructured":"Sell S, Leffert HL (2008) Liver cancer stem cells. J Clin Oncol 26(17):2800\u20132805","journal-title":"J Clin Oncol"},{"issue":"7015","key":"1065_CR68","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396\u2013401","journal-title":"Nature"},{"issue":"30","key":"1065_CR69","doi-asserted-by":"crossref","first-page":"11154","DOI":"10.1073\/pnas.0603672103","volume":"103","author":"PP Szotek","year":"2006","unstructured":"Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, Donahoe PK (2006) Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 103(30):11154\u201311159","journal-title":"Proc Natl Acad Sci USA"},{"issue":"17","key":"1065_CR70","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1200\/JCO.2008.17.6941","volume":"26","author":"BM Boman","year":"2008","unstructured":"Boman BM, Huang E (2008) Human colon cancer stem cells: a new paradigm in gastrointestinal oncology. J Clin Oncol 26(17):2828\u20132838","journal-title":"J Clin Oncol"},{"issue":"17","key":"1065_CR71","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1200\/JCO.2007.15.2603","volume":"26","author":"S Takaishi","year":"2008","unstructured":"Takaishi S, Okumura T, Wang TC (2008) Gastric cancer stem cells. J Clin Oncol 26(17):2876\u20132882","journal-title":"J Clin Oncol"},{"issue":"3","key":"1065_CR72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.stem.2007.06.002","volume":"1","author":"PC Hermann","year":"2007","unstructured":"Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1(3):313\u2013323","journal-title":"Cell Stem Cell"},{"issue":"17","key":"1065_CR73","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2007.15.8428","volume":"26","author":"CA Huff","year":"2008","unstructured":"Huff CA, Matsui W (2008) Multiple myeloma cancer stem cells. J Clin Oncol 26(17):2895\u20132900","journal-title":"J Clin Oncol"},{"issue":"6","key":"1065_CR74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.urolonc.2008.07.009","volume":"26","author":"FR Moltzahn","year":"2008","unstructured":"Moltzahn FR, Volkmer JP, Rottke D, Ackermann R (2008) \u201cCancer stem cells\u201d-lessons from Hercules to fight the Hydra. Urol Oncol 26(6):581\u2013589","journal-title":"Urol Oncol"},{"issue":"4\u20135","key":"1065_CR75","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.drup.2010.07.001","volume":"13","author":"Z Wang","year":"2010","unstructured":"Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S, Sarkar FH (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13(4\u20135):109\u2013118","journal-title":"Drug Resist Updat"},{"issue":"2","key":"1065_CR76","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2010.02.003","volume":"20","author":"U Koch","year":"2010","unstructured":"Koch U, Krause M, Baumann M (2010) Cancer stem cells at the crossroads of current cancer therapy failures\u2013radiation oncology perspective. Semin Cancer Biol 20(2):116\u2013124","journal-title":"Semin Cancer Biol"},{"issue":"7","key":"1065_CR77","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrc2419","volume":"8","author":"M Baumann","year":"2008","unstructured":"Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8(7):545\u2013554","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1065_CR78","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/09553000902836404","volume":"85","author":"M Baumann","year":"2009","unstructured":"Baumann M, Krause M, Thames H, Trott K, Zips D (2009) Cancer stem cells and radiotherapy. Int J Radiat Biol 85(5):391\u2013402","journal-title":"Int J Radiat Biol"},{"issue":"1","key":"1065_CR79","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.biocel.2009.06.010","volume":"42","author":"S Fulda","year":"2010","unstructured":"Fulda S, Pervaiz S (2010) Apoptosis signaling in cancer stem cells. Int J Biochem Cell Biol 42(1):31\u201338","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"1065_CR80","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.critrevonc.2007.09.004","volume":"66","author":"G Iannolo","year":"2008","unstructured":"Iannolo G, Conticello C, Memeo L, De Maria R (2008) Apoptosis in normal and cancer stem cells. Crit Rev Oncol Hematol 66(1):42\u201351","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1065_CR81","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3324\/haematol.10279","volume":"92","author":"U Testa","year":"2007","unstructured":"Testa U, Riccioni R (2007) Deregulation of apoptosis in acute myeloid leukemia. Haematologica 92(1):81\u201394","journal-title":"Haematologica"},{"issue":"6","key":"1065_CR82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ctrv.2008.03.125","volume":"34","author":"TC Johannessen","year":"2008","unstructured":"Johannessen TC, Bjerkvig R, Tysnes BB (2008) DNA repair and cancer stem-like cells\u2013potential partners in glioma drug resistance? Cancer Treat Rev 34(6):558\u2013567","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"1065_CR83","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2009.08.010","volume":"289","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Shi S, Yen Y, Brown J, Ta JQ, Le AD (2010) A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289(2):151\u2013160","journal-title":"Cancer Lett"},{"issue":"4","key":"1065_CR84","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.bbrc.2007.01.159","volume":"355","author":"J Neuzil","year":"2007","unstructured":"Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ (2007) Tumour-initiating cells versus cancer \u2018stem\u2019 cells and CD133: what\u2019s in the name? Biochem Biophys Res Commun 355(4):855\u2013859","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1065_CR85","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.bjc.6604242","volume":"98","author":"EM Hurt","year":"2008","unstructured":"Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL (2008) CD44+\u00a0CD24(\u2212) prostate cells are early cancer progenitor\/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98(4):756\u2013765","journal-title":"Br J Cancer"},{"issue":"1","key":"1065_CR86","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pharmthera.2008.04.008","volume":"119","author":"RC Zhao","year":"2008","unstructured":"Zhao RC, Zhu YS, Shi Y (2008) New hope for cancer treatment: exploring the distinction between normal adult stem cells and cancer stem cells. Pharmacol Ther 119(1):74\u201382","journal-title":"Pharmacol Ther"},{"issue":"Pt 16","key":"1065_CR87","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1242\/jcs.01222","volume":"117","author":"GD Richardson","year":"2004","unstructured":"Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT (2004) CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 117(Pt 16):3539\u20133545","journal-title":"J Cell Sci"},{"issue":"Suppl 1","key":"1065_CR88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/stem.5530150826","volume":"15","author":"JE Dick","year":"1997","unstructured":"Dick JE, Bhatia M, Gan O, Kapp U, Wang JC (1997) Assay of human stem cells by repopulation of NOD\/SCID mice. Stem Cells 15(Suppl 1):199\u2013203 discussion 204\u2013197","journal-title":"Stem Cells"},{"issue":"5","key":"1065_CR89","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.cell.2009.08.017","volume":"138","author":"M Shackleton","year":"2009","unstructured":"Shackleton M, Quintana E, Fearon ER, Morrison SJ (2009) Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 138(5):822\u2013829","journal-title":"Cell"},{"issue":"6859","key":"1065_CR90","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","volume":"414","author":"T Reya","year":"2001","unstructured":"Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105\u2013111","journal-title":"Nature"},{"key":"1065_CR91","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-59259-411-5","volume-title":"Stem Cells Handbook","author":"S Sell","year":"2004","unstructured":"Sell S (2004) Stem Cells Handbook. Humana Press Inc, New Jersey"},{"issue":"1","key":"1065_CR92","first-page":"25","volume":"1756","author":"SJ Miller","year":"2005","unstructured":"Miller SJ, Lavker RM, Sun TT (2005) Interpreting epithelial cancer biology in the context of stem cells: tumor properties and therapeutic implications. Biochim Biophys Acta 1756(1):25\u201352","journal-title":"Biochim Biophys Acta"},{"issue":"9","key":"1065_CR93","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ejca.2006.01.041","volume":"42","author":"IC Mackenzie","year":"2006","unstructured":"Mackenzie IC (2006) Stem cell properties and epithelial malignancies. Eur J Cancer 42(9):1204\u20131212","journal-title":"Eur J Cancer"},{"issue":"1","key":"1065_CR94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1582-4934.2007.00170.x","volume":"12","author":"JX Gao","year":"2008","unstructured":"Gao JX (2008) Cancer stem cells: the lessons from pre-cancerous stem cells. J Cell Mol Med 12(1):67\u201396","journal-title":"J Cell Mol Med"},{"issue":"4","key":"1065_CR95","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.surg.2006.12.015","volume":"141","author":"EH Huang","year":"2007","unstructured":"Huang EH, Heidt DG, Li CW, Simeone DM (2007) Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 141(4):415\u2013419","journal-title":"Surgery"},{"issue":"5","key":"1065_CR96","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2007.11.019","volume":"131","author":"K Takahashi","year":"2007","unstructured":"Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861\u2013872","journal-title":"Cell"},{"issue":"1","key":"1065_CR97","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.stem.2007.05.012","volume":"1","author":"S Yamanaka","year":"2007","unstructured":"Yamanaka S (2007) Strategies and new developments in the generation of patient-specific pluripotent stem cells. Cell Stem Cell 1(1):39\u201349","journal-title":"Cell Stem Cell"},{"issue":"11","key":"1065_CR98","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/1535-7163.MCT-10-0504","volume":"9","author":"YW Chen","year":"2010","unstructured":"Chen YW, Chen KH, Huang PI, Chen YC, Chiou GY, Lo WL, Tseng LM, Hsu HS, Chang KW, Chiou SH (2010) Cucurbitacin I suppressed stem-like property and enhanced radiation-induced apoptosis in head and neck squamous carcinoma\u2013derived CD44(+)ALDH1(+) cells. Mol Cancer Ther 9(11):2879\u20132892","journal-title":"Mol Cancer Ther"},{"issue":"21","key":"1065_CR99","doi-asserted-by":"crossref","first-page":"6751","DOI":"10.1158\/1078-0432.CCR-08-1034","volume":"14","author":"L Du","year":"2008","unstructured":"Du L, Wang H, He L, Zhang J, Ni B, Wang X, Jin H, Cahuzac N, Mehrpour M, Lu Y, Chen Q (2008) CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14(21):6751\u20136760","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1065_CR100","doi-asserted-by":"crossref","first-page":"R59","DOI":"10.1186\/bcr1610","volume":"8","author":"C Sheridan","year":"2006","unstructured":"Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H (2006) CD44+\u00a0\/CD24\u2212 breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59","journal-title":"Breast Cancer Res"},{"issue":"2","key":"1065_CR101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.stem.2008.07.012","volume":"3","author":"CF Kim","year":"2008","unstructured":"Kim CF, Dirks PB (2008) Cancer and stem cell biology: how tightly intertwined? Cell Stem Cell 3(2):147\u2013150","journal-title":"Cell Stem Cell"},{"issue":"3","key":"1065_CR102","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ejcts.2009.03.063","volume":"36","author":"V Tirino","year":"2009","unstructured":"Tirino V, Camerlingo R, Franco R, Malanga D, La Rocca A, Viglietto G, Rocco G, Pirozzi G (2009) The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer. Eur J Cardiothorac Surg 36(3):446\u2013453","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4 Pt 2","key":"1065_CR103","first-page":"F563","volume":"273","author":"H Okada","year":"1997","unstructured":"Okada H, Danoff TM, Kalluri R, Neilson EG (1997) Early role of Fsp1 in epithelial-mesenchymal transformation. Am J Physiol 273(4 Pt 2):F563\u2013F574","journal-title":"Am J Physiol"},{"issue":"6","key":"1065_CR104","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420\u20131428","journal-title":"J Clin Invest"},{"issue":"5","key":"1065_CR105","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.urolonc.2008.12.018","volume":"28","author":"H Wallerand","year":"2010","unstructured":"Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, Reiter RE, Ferriere JM (2010) The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and\/or metastatic bladder and prostate cancers. Urol Oncol 28(5):473\u2013479","journal-title":"Urol Oncol"},{"issue":"2","key":"1065_CR106","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1349-7006.2009.01419.x","volume":"101","author":"M Iwatsuki","year":"2010","unstructured":"Iwatsuki M, Mimori K, Yokobori T, Ishi H, Beppu T, Nakamori S, Baba H, Mori M (2010) Epithelial-mesenchymal transition in cancer development and its clinical significance. Cancer Sci 101(2):293\u2013299","journal-title":"Cancer Sci"},{"issue":"17","key":"1065_CR107","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1101\/gad.13.17.2207","volume":"13","author":"R Maestro","year":"1999","unstructured":"Maestro R, Dei Tos AP, Hamamori Y, Krasnokutsky S, Sartorelli V, Kedes L, Doglioni C, Beach DH, Hannon GJ (1999) Twist is a potential oncogene that inhibits apoptosis. Genes Dev 13(17):2207\u20132217","journal-title":"Genes Dev"},{"issue":"10","key":"1065_CR108","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1101\/gad.294104","volume":"18","author":"S Vega","year":"2004","unstructured":"Vega S, Morales AV, Ocana OH, Valdes F, Fabregat I, Nieto MA (2004) Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 18(10):1131\u20131143","journal-title":"Genes Dev"},{"issue":"7","key":"1065_CR109","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","volume":"117","author":"J Yang","year":"2004","unstructured":"Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A, Weinberg RA (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117(7):927\u2013939","journal-title":"Cell"},{"issue":"9","key":"1065_CR110","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nrc1694","volume":"5","author":"T Brabletz","year":"2005","unstructured":"Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Opinion: migrating cancer stem cells\u2014an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744\u2013749","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"1065_CR111","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1158\/0008-5472.CAN-04-3785","volume":"65","author":"WK Kwok","year":"2005","unstructured":"Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, Zhang X, Chua CW, Chan KW, Chan FL, Glackin C, Wong YC, Wang X (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65(12):5153\u20135162","journal-title":"Cancer Res"},{"issue":"2","key":"1065_CR112","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/sj.onc.1207128","volume":"23","author":"X Wang","year":"2004","unstructured":"Wang X, Ling MT, Guan XY, Tsao SW, Cheung HW, Lee DT, Wong YC (2004) Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 23(2):474\u2013482","journal-title":"Oncogene"},{"issue":"6","key":"1065_CR113","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","volume":"7","author":"H Peinado","year":"2007","unstructured":"Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415\u2013428","journal-title":"Nat Rev Cancer"},{"issue":"6A","key":"1065_CR114","first-page":"3415","volume":"22","author":"IB Fuchs","year":"2002","unstructured":"Fuchs IB, Lichtenegger W, Buehler H, Henrich W, Stein H, Kleine-Tebbe A, Schaller G (2002) The prognostic significance of epithelial-mesenchymal transition in breast cancer. Anticancer Res 22(6A):3415\u20133419","journal-title":"Anticancer Res"},{"issue":"12","key":"1065_CR115","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/nm.2236","volume":"16","author":"H Tanaka","year":"2010","unstructured":"Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M, Rettig MB, Wainberg ZA, Reiter RE (2010) Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 16(12):1414\u20131420","journal-title":"Nat Med"},{"issue":"4","key":"1065_CR116","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.cell.2008.03.027","volume":"133","author":"SA Mani","year":"2008","unstructured":"Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704\u2013715","journal-title":"Cell"},{"issue":"4","key":"1065_CR117","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/bcr2333","volume":"11","author":"B Aktas","year":"2009","unstructured":"Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S (2009) Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 11(4):R46","journal-title":"Breast Cancer Res"},{"issue":"7","key":"1065_CR118","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1073\/pnas.0914721107","volume":"107","author":"N Kyprianou","year":"2010","unstructured":"Kyprianou N (2010) ASK-ing EMT not to spread cancer. Proc Natl Acad Sci USA 107(7):2731\u20132732","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"1065_CR119","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10585-008-9183-1","volume":"25","author":"HE Zhau","year":"2008","unstructured":"Zhau HE, Odero-Marah V, Lue HW, Nomura T, Wang R, Chu G, Liu ZR, Zhou BP, Huang WC, Chung LW (2008) Epithelial to mesenchymal transition (EMT) in human prostate cancer: lessons learned from ARCaP model. Clin Exp Metastasis 25(6):601\u2013610","journal-title":"Clin Exp Metastasis"},{"issue":"15","key":"1065_CR120","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512","journal-title":"N Engl J Med"},{"issue":"15","key":"1065_CR121","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351(15):1513\u20131520","journal-title":"N Engl J Med"},{"issue":"12","key":"1065_CR122","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/nrc1232","volume":"3","author":"R Pardal","year":"2003","unstructured":"Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895\u2013902","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"1065_CR123","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1200\/JCO.1995.13.9.2278","volume":"13","author":"WT Stephenson","year":"1995","unstructured":"Stephenson WT, Poirier SM, Rubin L, Einhorn LH (1995) Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide, and bleomycin. J Clin Oncol 13(9):2278\u20132280","journal-title":"J Clin Oncol"},{"issue":"25","key":"1065_CR124","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.1073\/pnas.252462599","volume":"99","author":"ML Guzman","year":"2002","unstructured":"Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RM, Szilvassy SJ, Jordan CT (2002) Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 99(25):16220\u201316225","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"1065_CR125","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.intimp.2009.01.014","volume":"9","author":"R Tasso","year":"2009","unstructured":"Tasso R, Pennesi G (2009) When stem cells meet immunoregulation. Int Immunopharmacol 9(5):596\u2013598","journal-title":"Int Immunopharmacol"},{"issue":"15","key":"1065_CR126","doi-asserted-by":"crossref","first-page":"9864","DOI":"10.1073\/pnas.142298299","volume":"99","author":"M Drukker","year":"2002","unstructured":"Drukker M, Katz G, Urbach A, Schuldiner M, Markel G, Itskovitz-Eldor J, Reubinoff B, Mandelboim O, Benvenisty N (2002) Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 99(15):9864\u20139869","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1065_CR127","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1634\/stemcells.2007-0554","volume":"26","author":"Z Selmani","year":"2008","unstructured":"Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, Obert L, Borg C, Saas P, Tiberghien P, Rouas-Freiss N, Carosella ED, Deschaseaux F (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+\u00a0CD25highFOXP3+\u00a0regulatory T cells. Stem Cells 26(1):212\u2013222","journal-title":"Stem Cells"},{"issue":"2","key":"1065_CR128","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11060-006-9265-3","volume":"83","author":"A Wu","year":"2007","unstructured":"Wu A, Wiesner S, Xiao J, Ericson K, Chen W, Hall WA, Low WC, Ohlfest JR (2007) Expression of MHC I and NK ligands on human CD133+\u00a0glioma cells: possible targets of immunotherapy. J Neurooncol 83(2):121\u2013131","journal-title":"J Neurooncol"},{"issue":"10","key":"1065_CR129","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00262-009-0672-0","volume":"58","author":"C Gedye","year":"2009","unstructured":"Gedye C, Quirk J, Browning J, Svobodova S, John T, Sluka P, Dunbar PR, Corbeil D, Cebon J, Davis ID (2009) Cancer\/testis antigens can be immunological targets in clonogenic CD133+\u00a0melanoma cells. Cancer Immunol Immunother 58(10):1635\u20131646","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1065_CR130","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/mc.20614","volume":"49","author":"T Yawata","year":"2010","unstructured":"Yawata T, Nakai E, Park KC, Chihara T, Kumazawa A, Toyonaga S, Masahira T, Nakabayashi H, Kaji T, Shimizu K (2010) Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 49(6):532\u2013544","journal-title":"Mol Carcinog"},{"issue":"4","key":"1065_CR131","doi-asserted-by":"crossref","first-page":"R273","DOI":"10.1677\/ERC-10-0145","volume":"17","author":"RA Taylor","year":"2010","unstructured":"Taylor RA, Toivanen R, Risbridger GP (2010) Stem cells in prostate cancer: treating the root of the problem. Endocr Relat Cancer 17(4):R273\u2013R285","journal-title":"Endocr Relat Cancer"},{"key":"1065_CR132","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/1471-2407-9-202","volume":"9","author":"E Charafe-Jauffret","year":"2009","unstructured":"Charafe-Jauffret E, Ginestier C, Birnbaum D (2009) Breast cancer stem cells: tools and models to rely on. BMC Cancer 9:202","journal-title":"BMC Cancer"},{"issue":"6","key":"1065_CR133","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B","volume":"29","author":"G Murphy","year":"1996","unstructured":"Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A (1996) Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 29(6):371\u2013380","journal-title":"Prostate"},{"issue":"1","key":"1065_CR134","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/(SICI)1097-0045(19990401)39:1<54::AID-PROS9>3.0.CO;2-U","volume":"39","author":"GP Murphy","year":"1999","unstructured":"Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL (1999) Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39(1):54\u201359","journal-title":"Prostate"},{"issue":"7","key":"1065_CR135","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1517\/13543780902997928","volume":"18","author":"RA Madan","year":"2009","unstructured":"Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL (2009) Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 18(7):1001\u20131011","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"1065_CR136","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","volume":"28","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28(7):1099\u20131105","journal-title":"J Clin Oncol"},{"issue":"21","key":"1065_CR137","doi-asserted-by":"crossref","first-page":"10296","DOI":"10.1158\/0008-5472.CAN-07-2173","volume":"67","author":"SR Setlur","year":"2007","unstructured":"Setlur SR, Royce TE, Sboner A, Mosquera JM, Demichelis F, Hofer MD, Mertz KD, Gerstein M, Rubin MA (2007) Integrative microarray analysis of pathways dysregulated in metastatic prostate cancer. Cancer Res 67(21):10296\u201310303","journal-title":"Cancer Res"},{"issue":"3","key":"1065_CR138","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/pros.21062","volume":"70","author":"N Nadiminty","year":"2010","unstructured":"Nadiminty N, Dutt S, Tepper C, Gao AC (2010) Microarray analysis reveals potential target genes of NF-kappaB2\/p52 in LNCaP prostate cancer cells. Prostate 70(3):276\u2013287","journal-title":"Prostate"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1065-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-011-1065-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1065-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-011-1065-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T19:02:08Z","timestamp":1712516528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-011-1065-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,19]]},"references-count":138,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["1065"],"URL":"https:\/\/doi.org\/10.1007\/s00262-011-1065-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,19]]},"assertion":[{"value":"18 March 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}